CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today
The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough response rate.
4 minutes ago
Biotech's movers for the week of March 23rd and a look ahead to some key events for the sector next week
Reviewing some of biotech's biggest moves over the last week, including Kodiak, Enliven, Sarepta, Wave, and Maze.
3 days ago
Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases
He describes the science behind Coya's combination therapies, and programs targeting ALS (currently in a phase 2 study), FTD, and Alzheimer's.
3 days ago
.png){kind=logo}
